Evaluation of the functional parameters in scleroderma cases with pulmonary involvement

Tuberkuloz ve Toraks

Volumn 58, Issue 3, 2010, Pages 235-241

  Çelebi Sözener, Zeynep ^a   Karabiyikoǧlu, Gülseren ^a   Düzgün, Nurşen ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

6MWD; Carbon monoxide diffusion of the lungs (DLCO); Pulmomary hypertension; Scleroderma; St. George's respiratory questionnaire

Indexed keywords

CARBON MONOXIDE;

ADULT; ARTERIAL GAS; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DYSPNEA; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; HUMAN; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FUNCTION TEST; MALE; NON INVASIVE MEASUREMENT; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; QUESTIONNAIRE; SYSTEMIC SCLEROSIS;

BLOOD GAS ANALYSIS; CARBON MONOXIDE; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY; RADIOGRAPHY, THORACIC; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 77958105396     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. th ed. USA: McGraw-Hill Comp, 2001: 1937-45.
2. Atikcan Ş, Atalay F, Ernam D. Konnektif doku hastaliklari. Erdoǧan Y, Samurkaşoǧlu B (editörler). Diffüz Parankimal Akciǧer Hastaliklari. Ankara: Mesut Matbaacilik, 2004: 195-224.
3. Oksel F. Skleroderma. Doǧanavşargil E, Gümü şdiş G (editörler). Klinik Romatoloji El Kitabi. İzmir: İzmir Güven Kitabevi, 2003: 281-99.
4. Van Laar JM, Stolk J, Tyndall A. Skleroderma lung pathogenesis, evaluation and current therapy. Drugs 2007; 67: 985-96. (Pubitemid 46744475)
5. Charabaty S, Steen V. Pulmonary complications are the leading causes of scleroderma-related death. Managing lung involvement systemic sclerosis. J Musculoskel Med 2006; 23: 57.
6. Hoeper MM, Faulenbach C, Golpon H, et al. Combination theraphy with bosentan and sildenafil in idiopatic pulmoner arterial hypertension. ERJ 2004; 24: 1007-10. (Pubitemid 39642293)
7. Tores F, Gupta H, Murali S, et al. Gool-directed combination theraphy in pulmonary arterial hypertension study: design of COMPASS-3. Chest 2007; 132: 6335-581.
8. Galie N, Torbicki A, Barst R, et al. ECS guidelines on diagnosis and treatment of pulmonary arterial hypertension. European Heart Journal 2004; 25: 2243-78.
9. Manoussakis MN, Constantopoulos SH, Gharavi AE, Moutsopoulos HM. Pulmonary involvement in systemic Ssclerosis. Association with Scl-70 antibody and digital pitting. Chest 1987; 92: 509-513.
10. Racz H, Mehta S. Dyspnea due to pulmonary hypertension and interstitial lung disease in scleroderma: room for improvement in diagnosis and management. J Rheumatol 2006; 33: 1723.
11. Scheja A, Akesson A, Wollmer P, Wollheim FA. Early pulmonary disease in systemic sclerosis: a comparison between carbon monoxide transfer factor and static lung compliance. Annals of the Rheumatic Diseases 1993; 52: 725-9. (Pubitemid 23317571)
12. Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22.
13. Trad S, Amoura Z, Beigelman C, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung Disease. Arthritis and Rheumatism 2006; 54: 184-91. (Pubitemid 43122201)
14. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-24.
15. Mukerjee D, St. George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial pypertension in systemic sclerosis. Rheumatology 2004; 43: 461-6. (Pubitemid 38489363)
16. Steen VD, Graham G, Conte C, et al. Isolated diffusion capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 765-70.
17. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation of the extend of the disease on computed tomography. Arthritis Rheum 1997; 40: 1229-36.
18. Van Laar JM, Stolk J, Tyndall A. Scleroderma lung pathogenesis, evaluation and current therapy. Drugs 2007; 67: 985-96. (Pubitemid 46744475)
19. Launay D, Mouthon L, Hachulla E, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatology 2007; 34: 1005-11. (Pubitemid 46774846)
20. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-24.
21. Hsu VM, Moreyra AE, Shinnar M, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008; 35: 458-65. (Pubitemid 351374421)
22. Karabiyikoglu G, Akkoca Ö, Saryal S, Düzgün N. The relationship between pulmonary hemodynamics, arterial blood gases and ventilator tests in scleroderma. Tuberk Toraks 2002; 50: 5-11.
23. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-93 (Pubitemid 126719617)
24. Plastiras SC, Karadimitrakis SP, Kampolis C, et al. Determinants of pulmonary arterial hypertension in scleroderma. Semin Arthritis Rheum 2007; 36: 392-6. Epub 2007 Jan 3. (Pubitemid 46776817)
25. Villalba WO, Sampaio-Barros PD, Pereira MC, et al. Six minute walk test for evaluation of pulmonary disease severity in scleroderma patients. Chest 2007; 131: 217-22
26. Beretta L,Santaniello A, Lemos A, et al. Validity of the saint george's respiratory questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology 2007; 46: 296-301 (Pubitemid 46189792)